Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Published:2015-10 Issue:10 Volume:2 Page:e427-e437
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Lalezari Jacob P,Latiff Gulam H,Brinson Cynthia,Echevarría Juan,Treviño-Pérez Sandra,Bogner Johannes R,Thompson Melanie,Fourie Jan,Sussmann Pena Otto A,Mendo Urbina Fernando C,Martins Marcelo,Diaconescu Iulian G,Stock David A,Joshi Samit R,Hanna George J,Lataillade Max

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference17 articles.

1. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy;May;AIDS,2014

2. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada;Samji;PLoS One,2013

3. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up;Lee;PLoS One,2014

4. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years;Lodwick;Arch Intern Med,2010

5. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe;Nakagawa;J Acquir Immune Defic Syndr,2012

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study;HIV Medicine;2024-08-25

2. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab;Antiviral Research;2024-08

3. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV;AIDS;2024-07-02

4. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

5. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir;BMC Infectious Diseases;2024-02-23